Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

e:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... YORK , Oct. 24, 2014 ... Inc. (ACCP), a biopharmaceutical company advancing patient care ... 1-for-50 reverse split of its common stock effective ... 24, 2014. PlasmaTech,s common stock will trade on ... and temporary ticker symbol "ACCPD". After 20 days, ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open ... the pain management and clinical markets. The software increases ... by allowing users to highlight and review results that ... allows analysts to filter results by group or based ... eliminating the need to sift through analytes of no ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... Synthetic Genomes , , ... Venter Institute (JCVI), a not-for-profit genomic research organization, have published ... which the team can now assemble the whole bacterial genome, ... of DNA. Lead author Daniel G. Gibson, Ph.D. and his ...
... LAUDERDALE, Fla., Dec. 4 Imaging Diagnostic,Systems, Inc., (OTC ... announced today that a new study evaluating the CTLM ... December 2008 issue of Academic,Radiology. , ... , Alexander Poellinger, MD, a radiologist at ...
... that,it has initiated a Phase 2 clinical trial in ... dosing of a humanized monoclonal antibody,(MAb) that targets the ... pathway may lead to a targeted approach for,treating patients ... "Asthma can be ...
Cached Biology Technology:J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 2J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 3J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 4J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology 5Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3
(Date:10/15/2014)... ability to assess the pandemic risk from strains of ... must not allow ourselves to become complacent that the ... consortium of scientists. , Influenza pandemics arise when a ... to develop widespread immunity – spreads in the human ... past 100 years, the worst of which – the ...
(Date:10/15/2014)... 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market releases photos and video of ... on Monday October 13 th . Gino ... and angel investor Mr. Chad A. Verdi rang ... NXT-ID thanked his investors and employees "for their work and dedication ...
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... April 14, 2013) Through a collaborative genome-wide study ... that are associated with heart rate. Since heart ... could provide a better understanding of genetic regulation of ... targets for new drugs to treat cardiovascular disease. ...
... 14, 2013)Drug-eluting stents can keep clogged leg arteries ... being presented at the Society of Interventional Radiology,s ... "Peripheral arterial disease (or PAD) is becoming increasingly ... obesity and diabetes epidemics," said Robert A. Lookstein, ...
... Injury: Latest News on Clinical Trials of Interventions to ... 17, 2013, from 4:30 to 6:30 p.m., at Kessler ... special Grand Rounds is presented by the Northern New ... Cord Injury Project of the W. M. Keck Center ...
Cached Biology News:Mount Sinai study identifies new gene variations associated with heart rate 2Drug-coated stents prevent leg amputation 2The State of Spinal Cord Injury Grand Rounds 2
Rab GDP dissociation inhibitor beta...
... The MAX POWER 500V Programmable ... operate instruments which can handle virtually ... to high current blotting. It is ... text displays. The MAX POWER Programmable ...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Biology Products: